Journal of Oncology and Cancer Research

Dr. Hany Nabil Azzam is a highly accomplished Clinical Pharmacist and academic with over a decade of experience in pharmacy practice, teaching, and research. He currently serves as a Senior Clinical Pharmacist at Dr. Bakhsh Hospital, Jeddah, Saudi Arabia, where he provides optimal clinical pharmaceutical care, supports medical staff in drug therapy management, and contributes to patient safety initiatives. He earned his PhD in Pharmacology & Toxicology from Ain Shams University, focusing on the mitochondrial/metabolic axis in tamoxifen resistance in breast cancer. He also holds master’s degrees in Clinical Pharmacy and Clinical Pharmacology, as well as board certification in Pharmacotherapy (BCPS) from the American College of Clinical Pharmacists. In academia, Dr. Azzam has contributed significantly as a Lecturer, Assistant Lecturer, and Teaching Assistant at Heliopolis University, Cairo. He has supervised student projects, delivered lectures in clinical pharmacy, and participated in performance improvement initiatives. His research interests include cancer pharmacology, pharmacogenomics, clinical pharmacy practice, and quality improvement in healthcare.

• Oncology & Cancer Pharmacology
• Mitochondrial & Metabolic Pathways
• Molecular Biomarkers in Cancer
• Clinical Pharmacology & Therapeutics
• Clinical Pharmacology & Therapeutics
• Pharmacogenomics & Personalized Medicine

1.  Teaching and supervision in Clinical Pharmacy at Heliopolis University.

2.  Conducted and published multiple research studies in cancer pharmacology, mitochondrial mechanisms, and therapeutic biomarkers.

3.  Participation in international and national conferences, including the International Conference on Medical, Biological & Pharmaceutical Sciences (Prague, 2020), the Breast-Gynecological & Immunological International Cancer Conferences, and multiple Egyptian and Saudi scientific meetings.

4.  Delivered workshops and training sessions in Evidence-Based Medicine, Scientific Writing, Embryonic Stem Cell Research, and Educational Development.

5.  Active member in research collaborations on cancer resistance mechanisms, therapeutic drug monitoring, and pharmacotherapy optimization.

1.  MicroRNA 155 Expression and Treatment Response in Toxoplasma gondii-Infected Psoriasis Patients – 2025

2.  Multifaceted therapeutic potentials of catalpol, an iridoid glycoside: an updated comprehensive review – 2025

3.  Synopsis of colorectal cancer: prevalence, symptoms, screening, staging, risk factors, and treatment – 2025

4.  Low-Fat Diet and Vitamin D Effect on Induced NAFLD – 2024

5.  Chronotherapeutics & Chronopharmacology in viral infections: Narrative review on COVID-19 potential antiviral therapies and vaccines – 2024

6.  The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer – 2023

7.  Taurine upregulated 1: Prognostic biomarker in breast cancer – 2022

8.  Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer – 2022

9.  Vitamin D and Parathyroid Hormone and their Association with Symptoms of Fatigue and Quality of Life in Advanced Cancer Egyptian Patients – 2019